Expertise in
2
conditions

Dr. Dhimant Patel

Oncology
Bozeman Health Deaconess Regional Medical Center
915 Highland Blvd, 
Bozeman, MT 
Offers Telehealth
Expertise in
2
conditions
Bozeman Health Deaconess Regional Medical Center
915 Highland Blvd, 
Bozeman, MT 

Overview

Dhimant Patel is an Oncologist practicing medicine in Bozeman, Montana.

Dr. Patel is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Acute Hepatic Porphyria (AHP), Porphyria, Chronic B-Cell Leukemia (CBCL), and Richter Syndrome.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 6 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in WI

Hospital Affiliations

Bozeman Health Deaconess Hospital
Livingston Healthcare
Froedtert South Inc.

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Network Health
  • HMO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Bozeman Health Deaconess Regional Medical Center
915 Highland Blvd, Bozeman, MT 59715
Other Locations
Froedtert and the Medical College of Wisconsin Froedtert Hospital
9200 W Wisconsin Ave, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Afatinib Dimaleate, Cetuximab
Study Phase: Phase 2/Phase 3
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: May 01, 2026
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
View 5 Less Clinical Trials

3 Total Publications

New Landscape: Physician Compensation.
New Landscape: Physician Compensation.
Journal: JCO oncology practice
Published: December 22, 2020
Similar Doctors
Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

Praxis Pain Solutions Inc.

905 Highland Blvd Ste 4500, 
Bozeman, MT 
 (12.4 miles away)
406-414-5150
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Justin Bottsford is an Oncologist practicing medicine in Bozeman, Montana. Dr. Bottsford is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Hernia Surgery, and Oophorectomy.

Expertise in
43
conditions
Expertise in
43
conditions
Referral may be required

Bozeman Radiation Oncology PC

931 Highland Blvd Ste 3130, 
Bozeman, MT 
 (12.4 miles away)
406-414-5070
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Justin Thomas is an Oncologist practicing medicine in Bozeman, Montana. Dr. Thomas is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Appendix Cancer, Neuroendocrine Tumor, Familial Colorectal Cancer, and Lynch Syndrome.

Expertise in
34
conditions
Dr. Kenneth May
Hematology | Oncology
Expertise in
34
conditions
Dr. Kenneth May
Hematology | Oncology
Referral may be required

Bozeman Radiation Oncology PC

931 Highland Blvd Ste 3130, 
Bozeman, MT 
 (12.4 miles away)
406-585-5070
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kenneth May is a Hematologist and an Oncologist practicing medicine in Bozeman, Montana. Dr. May is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Angiosarcoma, Inflammatory Breast Cancer, and Large-Cell Immunoblastic Lymphoma.

Frequently Asked Questions about Dr. Dhimant Patel

How do I make an appointment with Dr. Dhimant Patel?

You can book an appointment with Dr. Dhimant Patel by calling their office at 406-414-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Dhimant Patel a top-rated expert for Acute Hepatic Porphyria (AHP)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Dhimant Patel is classified as an Advanced expert for Acute Hepatic Porphyria (AHP), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Dhimant Patel specialize in?

While Dr. Dhimant Patel is a Oncology, they have specific expertise in Acute Hepatic Porphyria (AHP), Porphyria, and Chronic B-Cell Leukemia (CBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Dhimant Patel participate in research or clinical trials?

Yes. Dr. Dhimant Patel has published 3 articles and abstracts on conditions like Acute Hepatic Porphyria (AHP). You can view a list of Dr. Dhimant Patel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Dhimant Patel accept my insurance?

Dr. Dhimant Patel accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 406-414-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patel's expertise for a condition
ConditionClose
      View All 94 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile